ArticleFrontiers in veterinary science2025
Treatment of canine pancreatitis using membrane-free stem cell extract and its anti-inflammatory effect.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine pancreatitis can lead to the digestion of nearby organs, and if untreated, it can develop into peritonitis. Widely used treatment as of now for acute pancreatitis (AP), however, largely depends on supportive treatment such as fluid therapy, antibiotics, and sufficient nutrient intake. Membrane-free stem cell extract (MF-STEM) is a protein mixture and other bioactive molecules derived from human adipose stem cells. MF-STEM is known for its anti-inflammatory and regenerative effects. This study was a vehicle-controlled clinical study. One hundred and forty-five canine pancreatitis patients with pancreatitis participated in this study with owners' consent. Following the owners' consent, 63 dogs received MF-STEM cell therapy with conventional therapy, and 82 dogs received conventional therapy. All participants had their cPL and CRP measured to evaluate their clinical progression. At the time of discharge, the survival rate in the MF-STEM cell therapy group survived (survival 92% and mortality 8%) more than the control group (survival 46% and mortality 54%). The authors suppose that MF-STEM cell increases survival of pancreatitis patients by modulating inflammatory cytokines. There were no side effects observed, such as allergic reactions and hypersensitivity reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.